Atézolizumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Atézolizumab" in French language version.

refsWebsite

Global rank French rank

2,393^rd place

506^th place

234^th place

147^th place

2,374^th place

298^th place

9,562^nd place

535^th place

low place

7,741^st place

447^th place

1,409^th place

68^th place

67^th place

8,603^rd place

517^th place

ascopubs.org

McDermott DF, Sosman JA, Sznol M et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study, J Clin Oncol, 2016;34:833–842

europa.eu

ema.europa.eu

(en) « Tecentriq - European Medicines Agency », sur European Medicines Agency, 17 septembre 2018 (consulté le 2 septembre 2020).

fda.gov

accessdata.fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf

has-sante.fr

https://www.has-sante.fr/upload/docs/application/pdf/2018-12/tecentriq_13122018_avis_efficience.pdf.

nature.com

Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 2014;515:563–567
Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 2014;515:558–562

nejm.org

Horn L, Mansfield AS, Szczęsna A et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, N Engl J Med, 2018;379:2220-2229
Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 2020;382:1894-1905

sante.fr

agence-prd.ansm.sante.fr

« Autorisation - Minigraphie », sur sante.fr (consulté le 2 mai 2023).

thelancet.com

Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, randomised, controlled multicentre trial, Lancet, 2017;389:255–265
Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 2016;387:1909–1920
Balar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, two-cohort, phase 2 trial, Lancet, 2017;389:67–76